How much does retatrutide typically cost?

There is no official public retail price for retatrutide at this time, because Lilly says it is not yet available for public use and it remains investigational. Any prices you see online are from non-approved channels and are not a reliable benchmark for an FDA-approved commercial product. That is an inference from its current investigational status and lack of public availability.

What are the risks of retatrutide peptide?

The main risks reported so far in trials have been gastrointestinal adverse events , especially nausea, diarrhea, vomiting, and constipation . Lilly’s March 2026 Phase 3 update also reported dose-related discontinuations due to adverse events and some cases of dysesthesia . Because retatrutide is still investigational, its full safety profile is still being evaluated .

Where can you buy retatrutide?

Factually, Lilly says retatrutide is not yet available for public use and is legally available only to participants in Lilly’s clinical trials . The FDA has also warned about companies illegally selling products labeled as semaglutide, tirzepatide, or retatrutide, including products falsely labeled “for research purposes” or “not for human consumption.”

Is retatrutide similar to Ozempic?

They are similar in one important way , because both involve GLP-1 signaling , but they are not the same drug . Ozempic is semaglutide , an FDA-approved GLP-1 receptor agonist . Retatrutide is an investigational triple agonist that targets GIP, GLP-1, and glucagon receptors .

How do people get retatrutide?

At the moment, the legitimate route described by Lilly is participation in Lilly-sponsored clinical trials . It has not been approved by the FDA, and Lilly explicitly warns people not to consider products claiming to be retatrutide outside those trials.

When can I buy retatrutide?

There is no announced public launch date yet . Lilly says availability depends on the completion of ongoing trials and the regulatory review process. Lilly also says additional results from the retatrutide clinical program are expected over the next year, and current pipeline materials show multiple Phase 3 programs underway.

How much retatrutide per week?

There is no FDA-approved weekly dose for retatrutide as of April 2, 2026. Trial dosing has varied by study protocol, so there is no single approved standard weekly amount for public use.

Is anything better than Ozempic for weight loss?

In head-to-head obesity trial data , tirzepatide produced greater average weight loss than semaglutide at 72 weeks, about 20.2% vs 13.7% . Retatrutide has shown very large weight-loss results in phase 2 studies, but because it is still investigational, the clearest approved comparison today is tirzepatide outperforming semaglutide in that trial setting.

RETA is presented on this page as a research-grade peptide for laboratory use. The product listing describes it as a 39-amino-acid, unimolecular peptide used in research settings to explore multi-receptor signaling.

Is a COA available for RETA?

Yes. The page states that each batch is supported by a lot-specific COA , with analytical data such as HPLC and MS available by batch when provided.

Back to Products

Peptide Researches RETA 10 MG product image showing the branded box, QR code, purity details, and matching vial on a clean studio background

1 / 7

RETA 10 MG by Peptide Researches displayed with the product box, QR code, purity information, and labeled vial.

RETA

Q: What does retatrutide peptide do for you?

Retatrutide is an investigational triple hormone receptor agonist . It activates GIP, GLP-1, and glucagon receptors , and in clinical studies it has been evaluated for effects on body weight and glycemic measures . In a phase 2 obesity trial, it produced substantial average weight reduction over 48 weeks, but it is still under study and is not FDA-approved .

Reta Research Grade (RUO) is a 39–amino acid, unimolecular peptide used in laboratory research settings to explore multi-receptor signaling (GIP / GLP-1 / glucagon [GCG]).

For laboratory research use only. Not intended for use in humans or animals.

$149.00

All Peptide Researches compounds are supplied strictly for in-vitro research use only. Each batch is tested using High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS), with typical purity ≥ 99% as documented in the accompanying COA.

Select Variation:

Quantity

(Max 99)

Category:Incretin Mimetics

Reta is supplied as a lyophilized white powder with ≥99% purity (HPLC) and endotoxin < 1.0 EU/mg. molecule includes a C20 fatty diacid moiety associated with albumin binding and extended stability in reported preclinical contexts. However, these characteristics are provided for technical reference only and should be interpreted within the limits of the available research.

Product Specifications

Purity (HPLC)	≥99%
Appearance	White to off-white lyophilized powder
Material Type	Research-grade
Molecular Formula	C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight	4731 g/mol
CAS Number	2381089-83-2
Net Content	Varies by selected variant (choose mg option)
Solubility	See laboratory SOP (solvent selection depends on assay requirements)
Storage (Lyophilized)	Store protected from light and moisture; follow institutional SOPs
Storage (Prepared for assays)	Aliquot as needed; avoid repeated freeze–thaw; follow institutional SOPs
Intended Use	For research use only; not for human or veterinary use
Documentation	Lot-specific COA; analytical data (HPLC/MS) when available

Chemical Identity & Structural Mechanism

Reta is a synthetic, unimolecular peptide comprising 39 amino acids. In research discussions, it is commonly described as a multi-receptor ligand with activity being investigated across the glucagon receptor (GCGR) as well as GIP and GLP-1 receptor pathways. Consequently, some literature informally refers to this as a “triple-agonist” profile, although the functional balance can vary by assay design and experimental system.

Structure–activity context (SAR)

The peptide backbone is frequently described as GIP-inspired and includes modifications used to explore GCGR-associated signaling in laboratory models. Additionally, the molecule features a C20 fatty diacid moiety associated with albumin binding, which researchers evaluate for its potential to influence peptide stability and apparent exposure in preclinical settings. However, reported stability or persistence values are system-dependent and should be interpreted only within the specific study conditions.

Potency characterization (assay-dependent)

In vitro profiling often reports different relative activities across the three receptor targets depending on the assay format, species, and endpoints measured. Therefore, any “hierarchy” of receptor activity should be presented as an experimental observation (with assay details) rather than as an outcome-based objective.

Chemical structure of retatrutide

Branched RETA molecular structure diagram on a light gray background with colored atomic markers and chemical bond lines

a triple-hormone receptor agonist (GIP/GLP-1/Glucagon). The highlighted C20 fatty acid moiety facilitates albumin binding, extending the half-life to ~6 days for sustained metabolic research. kfd

Research Context & Clinical Insights

Public research references (background only)

Public registries and sponsor communications describe research programs that evaluate retatrutide (LY3437943) in controlled study settings. Any such references are provided strictly for informational context about the broader research landscape and do not imply intended use of this material outside laboratory research.

Liver fat imaging endpoints in published research

Peer-reviewed literature has reported imaging-based liver fat endpoints in controlled research settings involving retatrutide, with outcomes defined and interpreted within the specific study methods and populations described by the authors.

Endotoxin monitoring

Screened to <1.0 EU/mg to support laboratory workflows that require low-endotoxin materials.

For laboratory research use only. Not intended for use in humans or animals.

Regulatory & Compliance Statement

Regulatory note (U.S.)

Public trial registries list retatrutide (LY3437943) as an investigational compound in Phase 3 studies (including TRIUMPH and TRANSCEND program studies). It does not have FDA marketing authorization.

Sport governance note

The World Anti-Doping Agency (WADA) Prohibited List includes S2: Peptide hormones, growth factors, related substances, and mimetics. Competitive sport organizations may restrict substances in this category, and individuals are responsible for checking the rules that apply to them.

Use designation

For laboratory research use only. Not intended for use in humans or animals.

Analytical Documentation

Each batch is analytically verified and supported by a lot-specific Certificate of Analysis (COA). Use the COA portal to access available documentation by product and lot number. Documentation availability may vary by batch.

Storage & Stability

Lyophilized

Store at -20°C for optimal long-term stability (up to 2 years). The lyophilized form is stable at room temperature for brief periods during shipping and handling.

After Reconstitution

Use immediately for best results. If storage is required, aliquot and store at -80°C. Use within 30 days. Avoid repeated freeze-thaw cycles which may degrade peptide integrity.

Shipping Temperature

Products ship in insulated packaging with cold packs when ambient temperatures require it. Lyophilized peptides remain stable during standard transit times.

Research-Only Disclaimer

This product is intended for laboratory research use only (in vitro).

For research use only; not for human or veterinary use.
Not a drug, medicine, or dietary supplement.
Not intended to diagnose, treat, cure, or prevent any disease.
Must be handled by trained research personnel following institutional SOPs.
Purchaser is responsible for compliance with all applicable laws and regulations.

By purchasing this product, you confirm it will be used solely for legitimate research purposes.

Frequently Asked Questions

Retatrutide is an investigational triple hormone receptor agonist . It activates GIP, GLP-1, and glucagon receptors , and in clinical studies it has been evaluated for effects on body weight and glycemic measures . In a phase 2 obesity trial, it produced substantial average weight reduction over 48 weeks, but it is still under study and is not FDA-approved .

Storage & Stability

Lyophilized

Store at -20°C for up to 2 years. Stable at RT during shipping.

Reconstituted

Use immediately or store aliquots at -80°C. Use within 30 days.

Quality Assurance

Every batch from Peptide Researches undergoes rigorous HPLC & Mass Spectrometry testing to ensure >99% purity and correct molecular structure verification.

Research Use Only

This product is for laboratory research only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease.

Discover · Topic hubs

Research compound pages

Open a dedicated hub for long-form context and citations. Checkout stays on the main product page.